SCHEMBL27218936

SCHEMBL27218936

CCc1ccc(-c2noc(CSc3nc(C)cc(N)n3)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.71
▸ NPC1 O15118 4/20 0.71
▸ SMN1; SMN2 Q16637 4/20 0.71
▸ HTT P42858 3/20 0.71
▸ LMNA P02545 2/20 0.71
▸ TNKS2 Q9H2K2 3/20 0.49
▸ TDP1 Q9NUW8 3/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ SENP6 Q9GZR1 1/20 0.46
▸ MAPT P10636 5/20 0.45
▸ POLB P06746 1/20 0.45
▸ TSHR P16473 3/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TP53 P04637 4/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494430 0.87 SMN1; SMN2 (0.72) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218886 0.86 SMN1; SMN2 (0.70) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218874 0.85 HTT (0.69) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL31494448 0.82 RAB9A (0.64) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218761 0.81 RAB9A (0.64) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218688 0.80 ALDH1A1 (0.62) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218899 0.77 SMN1; SMN2 (0.58) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL22570696 0.77 RAB9A (0.44) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL27218810 0.76 NPC1 (0.61) RAB9ANPC1SMN1; SMN2HTTLMNA
SCHEMBL12525780 0.75 MAPT (0.61) RAB9ANPC1SMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 RAB9A 2474/4885NPC1 781/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback